BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10599932)

  • 1. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
    Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
    Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients.
    Vandel P; Haffen E; Nezelof S; Broly F; Kantelip JP; Sechter D
    Hum Psychopharmacol; 2004 Jul; 19(5):293-8. PubMed ID: 15252821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report.
    Haffen E; Vandel P; Bonin B; Vandel S
    Therapie; 1999; 54(6):768-70. PubMed ID: 10709456
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient.
    Conus P; Bondolfi G; Eap CB; Macciardi F; Baumann P
    Pharmacopsychiatry; 1996 May; 29(3):108-10. PubMed ID: 8738315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of modafinil and clomipramine as comedication in a narcoleptic patient.
    Grözinger M; Härtter S; Hiemke C; Griese EU; Röschke J
    Clin Neuropharmacol; 1998; 21(2):127-9. PubMed ID: 9579300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.
    Baumann P; Broly F; Kosel M; Eap CB
    Pharmacopsychiatry; 1998 Mar; 31(2):72. PubMed ID: 9562213
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Grapefruit juice as a contraindication? An approach in psychiatry].
    Vandel P; Regina W; Reix I; Vandel S; Sechter D; Bizouard P
    Encephale; 1999; 25(1):67-71. PubMed ID: 10205736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of clomipramine on CYP2D6 activity].
    Szewczuk-Bogusławska M; Kiejna A; Grzesiak M; Beszłej JA; Chlebowska I; Orzechowska-Juzwenko K; Milejski P
    Psychiatr Pol; 2007; 41(2):243-9. PubMed ID: 17598433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interaction between paroxetine and clomipramine as a possible reason for admission to a department of internal medicine].
    Skjelbo EF; Brøsen K
    Ugeskr Laeger; 1998 Sep; 160(39):5665-6. PubMed ID: 9771062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of desipramine toxicity with citalopram.
    Ashton AK
    J Clin Psychiatry; 2000 Feb; 61(2):144. PubMed ID: 10732663
    [No Abstract]   [Full Text] [Related]  

  • 15. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
    Stern RS; Marks IM; Wright J; Luscombe DK
    Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.
    Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P
    J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
    Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.